Accounts review for 2020

Adtec Healthcare is the European subsidiary for Adtec Plasma Technology in Japan. Our parent company is a renowned public company listed on the Tokyo Stock Exchange Market. As part of our annual accounts review, the reports are published on our websites:


Given the challenging year of 2020, we are grateful to announce a revenue of £52 million and net profit of £6.5 million. Our forecast revenue for 2021 is £55 million with a net profit £6.7 million. We are thankful to our faithful employees, customers and suppliers for their ongoing support much of which would not have been possible without their existence.


As part of the Adtec promise, we pledge to face the future with confidence, continue working to high quality standards and to continue our support to other businesses during the challenging times ahead.